Lenalidomid Zentiva (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex. This binding changes the complex’s substrate profile, leading to the ubiquitination and degradation of transcription factors Ikaros and Aiolos. The resulting actions include anti‑angiogenesis, modulation of the immune response, and direct inhibition of malignant cell growth.

The dosing regimen for Lenalidomid Zentiva is individualized. A prescribing physician determines the appropriate dose, schedule, and treatment duration based on the specific indication, disease stage, patient weight, renal function, and concurrent therapies. Patients should follow the exact instructions provided by their healthcare professional.

Lenalidomid Zentiva is classified as pregnancy category X because it is known to cause fetal harm. It is contraindicated in pregnancy and women of child‑bearing potential must use effective contraception. The drug is also not recommended while breastfeeding, as it may be excreted in milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Lenalidomid Zentiva belongs to the immunomodulatory imide drug (IMiD) class, similar to thalidomide and pomalidomide. Compared with thalidomide, lenalidomide generally offers a more favorable safety profile, especially regarding peripheral neuropathy, while retaining strong anti‑myeloma activity. Pomalidomide is often reserved for patients who have progressed after lenalidomide therapy, providing an additional option in later lines of treatment.

Store the tablets at ambient temperature, below 25 °C (77 °F). Keep the product in its original blister pack or container to protect it from moisture and light. Do not store in areas with high humidity or direct sunlight, and keep out of reach of children.

Lenalidomid Zentiva is administered orally as a tablet. It may be taken with or without food, according to the prescribing physician’s guidance. Patients should swallow the tablet whole with water and follow the prescribed schedule, typically on a cyclical basis (e.g., daily for a set number of days followed by a rest period).

Serious risks include venous thromboembolism, severe neutropenia or thrombocytopenia, secondary primary malignancies, and significant liver toxicity. Patients should be educated to recognize signs such as unexplained swelling, shortness of breath, fever, persistent bruising, or jaundice, and report these promptly to their healthcare provider.

Lenalidomid Zentiva is contraindicated in pregnant women, individuals with known hypersensitivity to lenalidomide or any component of the formulation, and patients with severe renal impairment unless dose adjustments are made under close supervision. Caution is also advised for patients with a history of thromboembolic events or uncontrolled infections.